In contrast, of the HER2 + interval cancers diagnosed between the two screening rounds, 58% were 2 cm or larger, and 62% had metastases in the axilla, while HER2 + breast cancers detected in screening nonparticipants were mostly larger than 2 cm (77%), node-positive (92%) and 62% of them had distant metastasis already at the time of diagnosis (Table 2). This evidence concerns the gene ERBB2 and cancer.